All In Biotech

Drug Trial Radar · NCT05553301

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older

Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

560

Actual

Start

Oct 3, 2022

Primary completion

Jan 19, 2024

Study completion Jan 19, 2024

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 2 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5407 compared to an active control (QIV standard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

Conditions

  • Influenza Immunization

Interventions

  • Quadrivalent Influenza mRNA Vaccine MRT5407Biological

    Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular Injection

  • Quadrivalent Recombinant Influenza VaccineBiological

    Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular Injection

  • Quadrivalent Influenza Standard Dose VaccineBiological

    Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe Route of Administration: Intramuscular Injection

  • Quadrivalent Influenza High-Dose VaccineBiological

    Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe Route of Administration: Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with immediate adverse events (AEs)Time frame: Within 30 minutes after injection
  2. Number of participants with solicited injection site and systemic reactionsTime frame: Up to 7 days after injection
  3. Number of participants with unsolicited AEsTime frame: Up to 28 days after injection
  4. Number of participants with medically attended adverse events (MAAE)sTime frame: Up to 28 days after injection
  5. Number of participants with serious adverse events (SAEs)Time frame: From Day one to Day 366
  6. Number of participants with out-of-range biological test resultsTime frame: Up to 8 days after injection
  7. Individual Hemagglutination inhibition (HAI) titerTime frame: At Day 1 and Day 29
  8. Percentage of participants with detectable antibody HAI titers greater than or equal to (≥) 10 [1/dil]Time frame: At Day 1 and Day 29
  9. Individual HAI titer ratioTime frame: At Day 1 and Day 29
  10. Number of participants archiving HAI seroconversion against AntigensTime frame: At Day 1 and Day 29
  11. Percentage of participants with antibody HAI titers greater than or equal to (≥) 40 [1/dil]Time frame: At Day 29
  12. Percentage of participants with 2-fold and 4-fold rise in HAI titersTime frame: At Day 1 and Day 29

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Peninsula Research Associates Site Number : 8400025

    Rolling Hills Estates, California

  • Optimal Research Site Number : 8400059

    San Diego, California

  • California Research Foundation Site Number : 8400008

    San Diego, California

  • Accel Clinical Research-Deland Clinical Research Unit Site Number : 8400052

    DeLand, Florida

  • SIMEDHealth, LLC Site Number : 8400024

    Gainesville, Florida

  • Indago Research and Health Center Site Number : 8400014

    Hialeah, Florida

  • Cenexel Research Centers of America Site Number : 8400048

    Hollywood, Florida

  • Dade Research Center Site Number : 8400011

    Miami, Florida

  • Suncoast Research Group, LLC Site Number : 8400038

    Miami, Florida

  • Florida International Research Center Site Number : 8400051

    Miami, Florida

  • Palm Beach Research Center Site Number : 8400020

    West Palm Beach, Florida

  • DM Clinical Research Site Number : 8400032

    Melrose Park, Illinois

  • DM Clinical Research - Chicago Site Number : 8400028

    River Forest, Illinois

  • Brengle Family Medicine Site Number : 8400005

    Indianapolis, Indiana

  • AMR Lexington Site Number : 8400054

    Lexington, Kentucky

  • AMR Kansas City Site Number : 8400006

    Kansas City, Missouri

  • Velocity Clinical Research Site Number : 8400003

    Omaha, Nebraska

  • Coastal Carolina Research Center - N Charleston Site Number : 8400010

    North Charleston, South Carolina

  • AMR Knoxville Site Number : 8400046

    Knoxville, Tennessee

  • Elligo Health Research Site Number : 8400056

    Austin, Texas

  • Sun Research Institute Site Number : 8400030

    San Antonio, Texas

  • Clinical Trials of Texas, Inc. Site Number : 8400026

    San Antonio, Texas

  • DM Clinical Research - Sugar Land Site Number : 8400031

    Sugar Land, Texas

  • Investigational Site Number : 6300003

    Barrio Sabana, Puerto Rico

  • Investigational Site Number : 6300002

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.